Skip to main content

Metastatic Castration-Resistant Prostate Cancer

Discover how Hightower’s research has transformed outcomes for metastatic castration-resistant prostate cancer patients.


Research Study of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-Resistant Prostate Cancer (mCRPC) is an advanced stage of prostate cancer where the cancer cells have spread to other parts of the body and no longer respond to hormone therapy. It can metastasize to various areas such as nearby lymph nodes, bones, bladder, rectum, liver, lungs, and potentially the brain.

Hightower clinical trial aimed to prospectively compare the effectiveness of an investigational drug with the standard hormone therapy used to diagnose individuals with metastatic Castration-Resistant Prostate Cancer.

Current Status

Not Recruiting

Study Count


Frequently Asked Questions

What are the long-term effects of Metastatic Castration-Resistant Prostate Cancer?

It can weaken your bones, increase fatigue, and lead to pain. Early diagnosis and treatment are crucial to manage these complications.

Can Metastatic Castration-Resistant Prostate Cancer be cured?

There is currently no cure for Metastatic Castration-Resistant Prostate Cancer, but treatment can significantly improve your quality of life and life expectancy.

What are the risks and benefits of participating in a clinical trial for mCRPC?

As with any treatment, there are potential side effects associated with the medications tested in clinical trials. However, you’ll be closely monitored with the chance to receive promising new therapies that might not be available elsewhere.

Why should you participate in a clinical trial for mCRPC?

Clinical trials for mCRPC offer access to potentially groundbreaking new therapies that could improve your response to treatment, extend life expectancy, or manage symptoms more effectively.